| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Matthew J Levine | |
| P2860 | cites work | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 |
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial | Q27301948 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| SGLT2 Inhibitors May Predispose to Ketoacidosis | Q28081173 | ||
| Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q28254549 | ||
| American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 | Q28384855 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications | Q34120717 | ||
| Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors | Q34222752 | ||
| Ipragliflozin: first global approval | Q34412028 | ||
| Tofogliflozin: first global approval | Q34420901 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus | Q34876148 | ||
| SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials | Q35181821 | ||
| Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition | Q35973255 | ||
| Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial | Q36402095 | ||
| Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin | Q36431654 | ||
| Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1) | Q36555418 | ||
| Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes | Q36798680 | ||
| Possible adverse effects of SGLT2 inhibitors on bone | Q36988902 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial | Q37278239 | ||
| Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial | Q37279276 | ||
| Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes | Q37325818 | ||
| Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus | Q37468469 | ||
| Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor | Q37589626 | ||
| Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans | Q37848043 | ||
| Biology of human sodium glucose transporters | Q37870037 | ||
| Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria | Q38188185 | ||
| The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. | Q38237987 | ||
| Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin | Q38379817 | ||
| Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus | Q38408749 | ||
| Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus | Q38439475 | ||
| POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS. | Q38541561 | ||
| Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects | Q39816362 | ||
| Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats | Q39999985 | ||
| Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial | Q42706050 | ||
| AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. | Q44176935 | ||
| Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial | Q44251536 | ||
| Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes | Q45348074 | ||
| Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes | Q47581268 | ||
| Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment | Q47998345 | ||
| Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment | Q47998377 | ||
| Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension | Q50448714 | ||
| Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers | Q50454359 | ||
| AACE/ACE comprehensive diabetes management algorithm 2015. | Q50931076 | ||
| Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. | Q51326175 | ||
| Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. | Q51748822 | ||
| Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. | Q53551539 | ||
| Luseogliflozin: First Global Approval | Q57485821 | ||
| Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors | Q63071417 | ||
| Empagliflozin as add-on to metformin in people with Type 2 diabetes | Q85270760 | ||
| Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes | Q86042170 | ||
| Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin | Q86519614 | ||
| Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes After Treatment With Empagliflozin | Q86592706 | ||
| Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes | Q86623452 | ||
| Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus | Q86932366 | ||
| Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial | Q87809056 | ||
| Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial | Q88117871 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 4 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| hydrocarbon | Q43648 | ||
| mechanism of action | Q3271540 | ||
| genitourinary system | Q4712977 | ||
| carbohydrate | Q11358 | ||
| empagliflozin | Q5373824 | ||
| gliflozins | Q20089925 | ||
| phase III clinical trial | Q42824827 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 405-423 | |
| P577 | publication date | 2016-06-13 | |
| P1433 | published in | Current Diabetes Reviews | Q15761978 |
| P1476 | title | Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials | |
| P478 | volume | 13 |
| Q92309828 | Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes |
| Q93349329 | Case - Fungal urosepsis after ureteroscopy in a patient on new generation of anti-hyperglycemic medication |
| Q89627944 | Dysplastic urothelial changes accompany empagliflozin administration in urinary bladder of experimental diabetes |
| Q57471302 | Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial |
| Q88688841 | Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial |
| Q89273102 | Empagliflozin: A Review in Type 2 Diabetes |
| Q93032468 | Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs |
| Q64891770 | Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. |
| Q28354224 | Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy |
| Q91868121 | Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages |
| Q42643753 | Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). |
Search more.